Global Monoclonal Antibodies In Veterinary Health Market

Monoclonal Antibodies In Veterinary Health Market Summary

The Global Monoclonal Antibodies In Veterinary Health Market Size Was Estimated at USD 1.04 Billion in 2024 and is Projected to Reach USD 7.25 Billion by 2035, Growing at a CAGR of 19.31% from 2025 to 2035. The growing prevalence of animal diseases, the need for targeted therapies, the development of antibody technology, the rising cost of pet healthcare, and the growing use of biologics for efficient treatment and disease prevention in animals are all driving the growth of the monoclonal antibody market in veterinary health.

Key Regional and Segment-Wise Insights

• In 2024, North America held the largest revenue share of over 21.5% and dominated the market globally.
• In 2024, the dermatology segment had the highest market share by application, accounting for 50.72%.
• In 2024, the veterinary hospitals segment had the biggest market share by end user.

Global Market Forecast and Revenue Outlook

• 2024 Market Size: USD 1.04 Billion
• 2035 Projected Market Size: USD 7.25 Billion
• CAGR (2025-2035): 19.31%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing region

The monoclonal antibodies in the veterinary health market primarily focus on using monoclonal antibody-based treatments for diagnosing, managing, and preventing animal diseases. These biologics provide accurate and efficient therapy choices for a range of infectious, inflammatory, and neoplastic disorders in pets and cattle by targeting particular antigens.  The main drivers of market growth include increasing pet ownership, together with rising animal infectious and chronic disease cases, and expanding public awareness about modern veterinary therapies. Monoclonal antibody therapy demand increases because of both the shift toward personalized medicine and growing financial support for animal healthcare services.

Technological advancements have significantly advanced the development and implementation of monoclonal antibodies within veterinary practice.  Next-generation antibody engineering, together with hybridoma technology and recombinant DNA technology, is enhancing the effectiveness and safety profiles of mAbs. Market development occurs because government programs, together with regulatory support, work to improve animal health standards and promote veterinary biologics research and advanced treatment solutions. The development of advanced monoclonal antibody therapeutics for veterinary use progresses through collaborative ventures between biotechnology companies and veterinary organizations.

Application Insights

In 2024, the dermatology segment accounted for the largest revenue share of 50.72% and dominated the monoclonal antibodies in veterinary health market. The high disease prevalence of atopic dermatitis, together with allergic dermatitis and chronic skin infections among pets, leads to this market dominance. For these ailments, monoclonal antibodies provide focused and efficient therapeutic alternatives that reduce inflammation and improve animal quality of life. Veterinary practitioners, together with pet owners now more aware of advanced skin treatment methods, are creating a higher demand for these products. The segment maintains its leading market position because researchers continuously develop new monoclonal antibody treatments for dermatology that expand the available product selection.

The other segment in the monoclonal antibodies in veterinary health market is expected to grow at the fastest CAGR during the forecast period. The segment includes therapeutic areas such as immunology, together with pain management, cancer, and gastrointestinal illnesses. The fast expansion of the market results from two main factors: expanding therapeutic applications for complicated chronic animal diseases and growing research on new monoclonal antibody treatments beyond dermatology. The market experiences growth in these sectors because veterinary professionals increasingly accept biologics, and companion and livestock animals require advanced, customized treatments. The rapid expansion of this segment will be driven by new antibody-based product development, together with ongoing biotechnology advancements.

End User Insights

The veterinary hospitals segment held the largest revenue share in 2024 and led the monoclonal antibodies in veterinary health market. The extensive availability of modern therapeutic and diagnostic capabilities in veterinary hospitals serves as the primary reason for this market domination since these facilities deliver monoclonal antibody treatments. Veterinary clinics play a vital role in introducing biologic medicines since they usually serve as the first medical facility for handling serious and long-term illnesses in animals. The use of targeted medicines, including monoclonal antibodies, receives backing from veterinary professionals who possess specialized knowledge. Rising investments in veterinary infrastructure, together with growing awareness of advanced treatment alternatives and increasing pet visit numbers, have solidified the leadership position of this segment.

During the forecast period, other segment of the monoclonal antibodies in the veterinary health market is expected to grow at a significant rate. The category includes specialist clinics together with academic veterinary centers and research institutes, which are actively adopting monoclonal antibody treatments for clinical and experimental purposes. Research collaborations between academic institutions and pharmaceutical companies focused on developing new biologics, together with expanding veterinary immunology and biotechnology research, represent the leading growth factors. Referral clinics, together with specialty clinics, have gained increasing popularity for managing complex medical cases that require advanced treatments, including monoclonal antibodies. The market sector will increase in importance because of rising awareness and better access to such therapies.

Regional Insights

In 2024, the monoclonal antibodies in the veterinary health market in North America held the largest market share of 42.57% and led the market globally. The leadership position stems from the combination of elevated pet ownership numbers and advanced veterinary medical facilities, together with increasing spending on companion animal health. The region benefits from early adoption of advanced treatments like monoclonal antibodies because of its strong biotech sector and major industry players. Pet owner education regarding individualized therapy treatments serves as a driving force for market demand. The market expansion occurs because of rising veterinary research funding and regulatory backing from agencies, including the FDA for veterinary biologics. The United States and Canada maintain their position as leaders in scientific progress and clinical application of monoclonal antibody treatments for animal health purposes.

Europe Monoclonal Antibodies In Veterinary Health Market Trends

The European monoclonal antibodies in the veterinary health market is expected to grow significantly during the forecast period because of the rising requirement for specialized biological treatments and increasing knowledge about modern veterinary treatment approaches. The region's increasing pet ownership rate, especially in Germany, France, and the UK, leads to enhanced focus on companion animal healthcare. The industry benefits from both the development of animal health biotech enterprises and improved veterinary service accessibility. The implementation of monoclonal antibody treatments receives support from government initiatives that promote animal care and disease prevention, together with veterinary innovation and regulatory backing. Research institutions and pharmaceutical companies work together to develop new, powerful veterinary biologics.

Asia Pacific Monoclonal Antibodies In Veterinary Health Market Trends

During the forecast period, the Asia Pacific monoclonal antibodies in veterinary health market is expected to grow at the fastest CAGR. The market expansion primarily stems from growing pet ownership numbers and advancing animal health knowledge, along with pet owners' rising spending power for modern treatment methods. The market for biologic medicines is expanding because of the fast development of veterinary healthcare facilities in China, India, Japan, and Australia. The market growth rate increases because of rising animal biotechnology investments alongside government health enhancement programs and foreign veterinary pharmaceutical companies entering the region. Veterinary services modernization will probably lead to substantial growth in demand for monoclonal antibodies as focused and efficient therapies.

Key Monoclonal Antibodies In Veterinary Health Companies:

The following are the leading companies in the monoclonal antibodies in veterinary health market. These companies collectively hold the largest market share and dictate industry trends.

• Zoetis
• Indian Immunologicals Ltd
• Elanco
• Boehringer Ingelheim GmbH
• Merck & Co, Inc.
• Virbac
• Others

Recent Developments

• In April 2025, Virbac acquired new monoclonal antibodies from MabGenesis, a Japanese company, to create therapeutic remedies for illnesses affecting dogs. Virbac will use the technology to broaden its range of veterinary treatments, while MabGenesis will get royalties, milestone payments, and license fees under the arrangement.
• In February 2025, based on post-approval real-world data, Zoetis revised the U.S. label for Librela (bedinvetmab injectable), a once-monthly therapy for canine osteoarthritis pain.  Since its 2023 introduction, Zoetis has treated more than a million dogs in the United States, reaffirming the product's efficacy and safety while offering doctors and pet owners more resources and support.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decision Advisors has segmented the monoclonal antibodies in veterinary health market based on the below-mentioned segments

Global Monoclonal Antibodies In Veterinary Health Market, By Application

• Dermatology
• Pain
• Others

Global Monoclonal Antibodies In Veterinary Health Market, By End User

• Veterinary Hospitals
• Others

Global Monoclonal Antibodies In Veterinary Health Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa